FDA staff flags concerns for Capricor's Duchenne heart disease therapy

FDA staff raised concerns about whether Capricor's deramiocel cell therapy has sufficient evidence of effectiveness for treating cardiomyopathy in Duchenne muscular dystrophy patients, according to briefing documents released ahead of an advisory committee meeting.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.